Pharmaseed Ltd’s Post

Capture and analyze CTCs to gain detailed biomarker and ‘omics cancer insights. New Celselect Slides™ 2.0, used with the Genesis Cell Isolation System https://lnkd.in/gfNw6JU2, accepts up to 10 mL liquid biopsy samples and contains 140,800 microchambers to provide high efficiency microfluidic size-based CTC capture. Recover CTCs for culture or analysis, or perform on-slide biomarker immunostaining. #CelselectSlides #CTC #singlecell

Exploring the molecular intricacy of CD19: a key player in immunotherapy! 🧬 Delving into the structure of the B-lymphocyte antigen CD19 with its distinctive domains and antibody binding sites. This molecular understanding is paving the way for groundbreaking advancements in targeted cancer treatments. #Immunotherapy #CD19 #CancerResearch #MolecularBiology #Biotech #Science #HealthcareInnovation #CART #shenclinicalservices

Explore how the HBICE® platform optimizes TCE cytotoxicity while minimizing adverse events like cytokine release syndrome (CRS) 🚀   Key Learning Objectives: 🔸Understand the Role of T Cell Engagers (TCEs) in Cancer Therapy 🔸Explore the Mechanism of Action (MOA) of CD3 TCEs 🔸Examine the CD3 HBICE® Platform’s Optimization for T Cell Engagement 🔸Recognize the Therapeutic Potential of CD3 HBICE® in Solid Tumors with Reduced Risk of Adverse Events   💡Download the white paper here to get more insights: https://lnkd.in/esybdyr3   #Immunotherapy #CancerResearch #TCellEngagers #TCE #CD3 #BispecificAntibodies #Biotech #HBICE #Immunotherapy

How can aligning cancer treatments with circadian rhythms improve outcomes? Ector et al. provide a high-throughput method [experimental and computational techniques] to optimize drug efficacy, paving the way for personalized medicine research. - - - Ector, C., Schmal, C., Didier, J. et al. Time-of-day effects of cancer drugs revealed by high-throughput deep phenotyping. Nat Commun 15, 7205 (2024). https://lnkd.in/dw_Nbcpn #Chronotherapy #CancerResearch #ComputationalBiomedicine - - -

#UHNInstagramoftheWeek 🧐 How do we equitably allocate scarce medical resources like CAR-T therapy to cancer patients? 🌐 CAR-T (chimeric antigen receptor T cell therapy) is a breakthrough therapy for advanced #bloodcancers. The demand for the therapy is rising, but there are challenges in providing the services, such as long wait time for manufacturing. To ethically prioritize patients for the therapy, Drs. Jennifer Bell & Christine Chen from PM Research published a three-step framework in the journal Blood to bring more procedural justice into this process. https://lnkd.in/gysEGkne

Detecting pancreatic cancer by urine analysis for tumor-derived microRNAs: This new noninvasive test demonstrates impressive sensitivity and specificity, achieving 97% sensitivity for early-stage detection (Stage I/IIA) and up to 95.7% specificity. It significantly outperforms traditional CA19-9 biomarkers, which show only 37.5% sensitivity in early stages, potentially making early diagnosis far more accessible. #PancreaticCancer #EarlyDetection #MicroRNA #Biomarkets #MedicalResearch DOI: 10.1016/j.eclinm.2024.102936

CAR T cell therapy has been shown to be effective in treating certain types of cancer, but it can come with a potentially serious side effect known as cytokine release syndrome (CRS). While CRS typically occurs within the first week following CAR T cell infusion, the underlying mechanisms behind it are not yet fully understood. However, a recent study by Tewari and colleagues sheds new light on this issue. By using proteomic techniques, they identified elevated plasma levels of neutrophil-associated proteins in 21 patients who received anti-CD19 CAR-T therapies and developed CRS. Notably, proteins such as myeloperoxidase, alpha-defensin 1, RETN, citrullinated histone H3, and calprotectin were found to be elevated. This observation suggests a potential novel mechanism that involves neutrophil dysregulation and hyperactivation in the genesis and susceptibility to CRS. Further research on this topic may lead to improved treatments for this serious side effect. #CARTcells #anti-CD19 CART therapy #Cytokine release syndrome

🔥 Have burning questions for the curators behind COSMIC Actionability? Here's your chance to get answers!   Join us on March 7 for an exclusive webinar featuring a live Q&A session with Dr. Steve Jupe, COSMIC Actionability's principal curator. Led by Dr. Kyle Nilson, this webinar will explore a series of use cases demonstrating how #cancer and #biopharma labs can harness COSMIC (Catalogue of Somatic Mutations in Cancer) to: ☑️ Evaluate genomic loci using COSMIC’s comprehensive coding and non-coding variant annotations ☑️ Integrate variants with curated findings and summaries of mutational impact and clinical actionability ☑️ Use mutational signatures for potential clinical diagnosis and drug development applications   Don't miss out! Register now ⬇️ #drugdevelopment #precisiononcology

ACTIVE loading of vesicles with drugs results in an intra-vesicular drug concentration significantly higher than in the loading medium. For example, the remote loading of liposomes with doxorubicin via an ammonium gradient (the prototype of ACTIVE loading) yields liposomes with drug concentrations inside the liposomes >100-fold the drug level in the loading medium. I severely doubt any of the "active drug loading" methods listed in this paper are able to achieve that. Baring a special interaction of the drug with lipid membranes or components already inside EVs, the intra-vesicular drug concentration can never be higher than in the loading medium, neither by electroporation, sonication, detergent treatment, extrusion nor by freeze-thawing cycles. All these 5 methods lack a driving force leading to an ACCUMULUATION of the drug inside the vesicle. The term "active loading" is wrongly used in this paper. I am happy to be challenged on my opinion, I am open for any discussion and if I am wrong, I would be happy to stand corrected.

Epigenetic factors like DNA methylation & histone modification shape cancer's landscape. Dive into https://bit.ly/3wc65Ti the evolving realm of targeted therapies, navigating obstacles in drug development for effective cancer treatment. #CancerTherapies #Epigenetics